Skip to content
Biophytis
LIVE HEALTHIER LONGER
Biophytis
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN

Author Archives: Antoine

October 22, 2018

Press ReleasesBy Antoine22 October 2018

Interim results 2018 and perspective on activity. Read the Press Release

October 10, 2018

MediaBy Antoine10 October 2018

Interview with Stanislas Veillet, CEO of Biophytis, at the European Large & Midcap Event, Paris.

October 01, 2018

MediaBy Antoine1 October 2018

Interview with Stanislas Veillet, CEO of Biophytis in Le Revenu TV

September 13, 2018

Press ReleasesBy Antoine13 September 2018

Biophytis obtains a €10 million loan with Kreos Capital. Read the Press Release

September 04, 2018

Press ReleasesBy Antoine4 September 2018

Biophytis Provides Enrollment Update in Its Phase 2b SARA-OBS and SARA-INT Studies of Sarconeos in Sarcopenia. Read the Press Release

August 30, 2018

Press ReleasesBy Antoine30 August 2018

BIOPHYTIS to Present at the H.C. Wainwright 20th Annual Global Investment Conference. Read the Press Release

July 26, 2018

Press ReleasesBy Antoine26 July 2018

BIOPHYTIS: 2017 Annual Report filed. Read the Press Release

July 02, 2018

Press ReleasesBy Antoine2 July 2018

Biophytis appoints a new Chief Medical Officer based in the USA. Read the Press Release

June 04, 2018

Press ReleasesBy Antoine4 June 2018

Results of the Extraordinary General Meeting held on June 4, 2018. Passing of all the resolutions. Read the Press Release

May 28, 2018

Press ReleasesBy Antoine28 May 2018

Biophytis receives favourable opinion from EMA for the Orphan Drug designation of Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release

←1
234567891011121314151617181920212223
…2425262728…
293031323334
35→
© Biophytis 2006-2025 - Mentions Légales
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
Footer Colonne 1 - Anglais
Go to Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok